Macugen pegaptanib sodium

ApprovedSmall molecule

Macugen pegaptanib sodium is one of 99 small molecule programs targeting Proliferative Diabetic Retinopathy. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Proliferative Diabetic RetinopathyActive, not recruiting

Age-Related Macular DegenerationActive, not recruiting

Retinal EdemaActive, not recruiting

Vascular DiseaseActive, not recruiting

Proliferative Diabetic RetinopathyApproved

Active, not recruiting

Retinal EdemaPreclinical

Active, not recruiting

Vascular DiseaseApproved

Active, not recruiting

Competition

Competitive Landscape

237 competitors in Age-Related Macular Degeneration

#DrugCompanyPhaseTrials

Lucentis

Roche

Phase 3

64 2

Eylea

Regeneron

Phase 3

44 3

Vabysmo

Roche

Phase 3

13 4

Beovu

Novartis

Phase 3

10 5

Macugen

Pfizer

Phase 3

6 6

Avastin

BBio-Thera Solutions

Phase 3

18 7

Retaane

AAlcon Research

Phase 3

5 8

Kenalog

BBausch Health Americas, Inc.

Phase 3

2 9

Forzinity

SStealth BioTherapeutics Inc.

Phase 3

2 10

Luye Pharma Conbercept

CChengdu Kanghong Biotech Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Proliferative Diabetic Retinopathy2 trials

A Single-Center Trial of Intravitreous Injections of Macugen (Pegaptanib Sodium) Given at Least 7 Days Before Vitrectomy Secondary To Tractional Retinal Detachment in Proliferative Diabetic Retinopathy

Completed·RRetina Institute of Hawaii·Phase 1·NCT01487070·5 enrolled

Macugen for Proliferative Diabetic Retinopathy Study With Extended Dosing (M-PDRS ED)

Unknown status·VValley Retina Institute·Phase 4·NCT01486771·30 enrolled

Vascular Disease1 trial

Pegaptanib for Retinal Edema Secondary to Diabetic Vascular Disease(Preserve) Study

Completed·VValley Retina Institute·Phase 4·NCT01486238·72 enrolled

Retinal Edema1 trial

A Single-Center Trial of High Frequency Pegaptanib for Rapid Restoration of VEGF Levels in Diabetic Retinal Edema

Available·RRetina Institute of Hawaii··NCT01487044

Age-Related Macular Degeneration1 trial

Macugen (Pegaptanib Sodium) Alone, Versus Macugen in Combination With PDT (Photodynamic Therapy) With Visudyne (Verteporfin) in Patients With Age-Related Macular Degeneration (AMD)

Terminated·EEyetech Pharmaceuticals·Phase 4·NCT00134667·360 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for Macugen pegaptanib sodium. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Macugen pegaptanib sodium compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Macugen pegaptanib sodium. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Eyetech Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: EEyetech Pharmaceuticals

Macugen pegaptanib sodium

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Proliferative Diabetic Retinopathy2 trials

Vascular Disease1 trial

Retinal Edema1 trial

Age-Related Macular Degeneration1 trial

References

Drug Info

Quick Facts

Related News